The effects of the combination of a murine monoclonal antibody (MAb) (20, 26, 29) . Past studies have supported the possibility that MAb specific for the lipopolysaccharide (LPS) 0 side chain of P. aeruginosa, which has serotype-specific opsonic activity, is a possible candidate for the treatment of P. aeruginosa pneumonia (5, 16, 19, 30) . Although a previous investigator (18) indicated that neutropenia adversely affects the therapeutic efficacy of antibody in pseudomonal pneumonia, hyperimmune intravenous immunoglobulin used in conjunction with tobramycin was shown to be efficacious against this disease in neutropenic animals. More recently, Collins and colleagues (2) showed a beneficial effect of combination therapy with a murine immunoglobulin Gl (IgGl) LPSreactive MAb and oral ciprofloxacin in a leukopenic rat model of systemic pseudomonal infection. Therefore, combination therapy with LPS-specific MAbs and antimicrobial agents appears to be an important strategy for treating P. aeruginosa pneumonia in neutropenic patients.
immunoglobulin G MAb and sparfloxacin in neutropenic patients with P. aeruginosa pneumonia.
Pneumonia caused by Pseudomonas aeruginosa is the highest cause of mortality in immunosuppressed or neutropenic patients (6, 17, 24) . Despite recent advances in antimicrobial agents against P. aeruginosa, a substantial reduction in mortality from nosocomial P. aeruginosa pneumonia has not resulted (1, 12) . Recently, considerable interest in passive immune therapy by the use of a monoclonal antibody (MAb) against P. aeruginosa infections has developed (20, 26, 29) . Past studies have supported the possibility that MAb specific for the lipopolysaccharide (LPS) 0 side chain of P. aeruginosa, which has serotype-specific opsonic activity, is a possible candidate for the treatment of P. aeruginosa pneumonia (5, 16, 19, 30) . Although a previous investigator (18) indicated that neutropenia adversely affects the therapeutic efficacy of antibody in pseudomonal pneumonia, hyperimmune intravenous immunoglobulin used in conjunction with tobramycin was shown to be efficacious against this disease in neutropenic animals. More recently, Collins and colleagues (2) showed a beneficial effect of combination therapy with a murine immunoglobulin Gl (IgGl) LPSreactive MAb and oral ciprofloxacin in a leukopenic rat model of systemic pseudomonal infection. Therefore, combination therapy with LPS-specific MAbs and antimicrobial agents appears to be an important strategy for treating P. aeruginosa pneumonia in neutropenic patients.
It has been demonstrated that several quinolone derivatives are useful in the treatment of P. aeruginosa pneumonia in normal and neutropenic guinea pigs (4, 9, 27) . Sparfloxacin (AT-4140) is a newly developed quinolone for oral use that has broad and potent antibacterial activity (14) . This compound is characterized by its excellent tissue penetration and long half-life in plasma and tissues (13) . Furthermore, sparfloxacin is bactericidal for P. aeruginosa at a * Corresponding author. concentration near the MIC and can be used prophylactically for fatal P. aeruginosa pneumonia in mice (10, 14) .
Our study was designed to evaluate the efficacy of an LPS-specific IgG3 MAb in conjunction with a suboptimal dose of oral sparfloxacin in a neutropenic mouse model of P. aeruginosa pneumonia.
MATERIALS AND METHODS
Reagents. Cyclophosphamide (Endoxan) was provided by Shionogi & Co., Ltd., Osaka, Japan. Sparfloxacin was provided in powder form by Dainippon Pharmaceutical Co., Ltd., Osaka, Japan. Prior to use, sparfloxacin was suspended in 0.5% tragacanth gum (Nacalai Tesque, Inc., Tokyo, Japan) for oral administration.
Bacteria and LPS. MAb R6-3F2 at a single dose of 500 ,ug and sparfloxacin with id purified P. aeruginosa It-1 LPS, produced multhat of 10 mice that received sparfloxacin alone. wer-migrating bands in a stepladder pattern on Determination of sparfloxacin levels. Levels of sparfloxacin blots (immunoblots) produced from sodium dodecyl in plasma and lung tissue after oral administration in neutro-)lyacrylamide gels of It-1 LPS. The negative conpenic mice challenged with P. aeruginosa It-1 at a dose of R6-3F2 did not bind It-1 LPS. 105 CFU were measured by bioassay by the procedures of mental pneumonia in neutropenic mice. SpecificNakamura et al. (13) . The plasma and lung tissues were -free female Slc:ICR mice (age, 5 weeks) were harvested from exsanguinated mice at 0.5, 1, 2, 4, 6, and 12
from Shizuoka Agricultural Cooperation Associah postadministration. The lungs were homogenized in 5 ml of Laboratory Animals. Animals were given sterile 1/15 M phosphate buffer (pH 7) per g of lung tissue, and the water. To induce a neutropenic condition in these homogenate was incubated at 80°C for 15 min. The plasma ) mg of cyclophosphamide per kg of body weight and lung homogenate were kept at -80°C until use. The tinistered subcutaneously two times once every maximum concentrations observed and the elimination halfr. On the fourth to sixth days after the first dose of lives of sparfloxacin in plasma and lung tissue were calcusphamide, the total leukocyte counts in the periphlated by linear least-squares regression (13) . J of the mice were less than 10% of the pretreatment Opsonophagocytic assays. Bacteria that were presensitized 4ig. 1). On day 4 after the first dose of cyclophoswith heat-inactivated mouse ascitic fluid containing MAb P. aeruginosa pneumonia was produced in the 1D3 (final concentration, 5 ,ug/ml) were resuspended in nic mice by intratracheal challenge with P. aerugiHanks' balanced salt solution containing 0.1% gelatin, 0.15 by a previously described procedure (16) . Infected mM CaCl1 and 1.0 mM MgCl2 (GHBSS +) to a cell density re monitored for survival for 7 days. Mice with of 5 x 10 CFU/ml. Human polymorphonuclear leukocytes nia induced by cyclophosphamide became ex-(PMNs) were isolated from blood by dextran sedimentation usceptible to intratracheal challenge with P. aerugand Ficoll-Hypaque density gradient centrifugation. Human L. The 50% lethal doses of the strain in normal and AMs were collected from healthy smokers by bronchoalvenic mice were determined by probit analysis to be olar lavage and were prepared as described previously (23) .
and 62 CFU per mouse, respectively. Quantitative
The AMs contained PMNs in less than 5% of total cells. cultures were performed at various times on samAMs and PMNs were suspended in GHBSS2' at a concennous blood and lung tissue from animals that were tration of 2.5 x 106/ml. Fresh absorbed normal human serum d by ether anesthesia. The lungs of exsanguinated (AbsNHS) was prepared by a previously published method e removed aseptically and were homogenized in 9 by using live homologous bacteria (15) . AbsNHS The reduction in bacterial counts in blood was greater than that in the lungs. Sparfloxacin (125 ,ug per mouse) alone rendered a greater killing of bacteria in lung and blood than did MAb 1D3 alone. The reduction in bacterial number in lung and blood and of lung weight in mice treated with sparfloxacin alone was also significant compared with the results for the untreated group (P < 0.01). Moreover, the combination therapy with MAb 1D3 and sparfloxacin exerted the highest level of killing of bacteria in lungs and blood. The decrease of bacterial numbers in lungs and the lung weights of mice resulting from the MAb 1D3 and sparfloxacin combination therapy was significant compared with the results for mice that received MAb 1D3 (P < 0.01) or sparfloxacin (P < 0.05) alone. The number of bacteria in the blood of mice that received the combination therapy was similarly reduced. Sparfloxacin levels. After oral administration of sparfloxacin at a dose of 125 ,ug (5 mg/kg), maximum concentrations of 0.9 + 0.1 ,ug/ml in plasma and 3.3 + 0.2 ,ug/g in lung tissue were achieved. The half-lives of sparfloxacin were 0.91 h in plasma and 0.43 h in lung. At 4 h postadministration, sparfloxacin levels in plasma and lungs were less than 0.1 pug/ml and 1 ,ug/g, respectively. There was no accumulation of sparfloxacin in plasma or lungs after serial oral administrations every 12 h. Oral administration of a suboptimal dose of sparfloxacin (5 mg/kg) achieved 3.6 times higher levels in lung tissue than in plasma (0.9 ,Lg/ml) with the present model. The elimination half-life of this drug in lungs was shorter than that in plasma.
In addition, the half-life of sparfloxacin in the plasma of infected mice was shorter than that in the plasma of uninfected mice (13) . This shortened half-life of sparfloxacin in plasma in the animal model described here may be related to the infected site. Although sparfloxacin levels in plasma and lung in the pneumonia model were less than 0.1 p,g/ml at 4 h postadministration, sparfloxacin in combination with MAb 1D3 was bactericidal against P. aeruginosa It-1 in vivo. The fact that sparfloxacin at concentrations greater than and near the MIC is bactericidal for P. aeruginosa (10) may have something to do with this result.
In the present study, we documented a significant increase in the survival rates of mice given combination therapy with MAb 1D3 and a suboptimal dose of oral sparfloxacin against intratracheal challenge with the It-1 strain at a dose of 105 CFU, while 100% of infected mice that received MAb 1D3 alone or sparfloxacin alone were killed. This combination effect of MAb 1D3 and sparfloxacin on the survival rate was supported by bacterial killing in the plasma and lung tissues of infected mice. The combination therapy provided intrapulmonary killing of bacteria at a magnitude of greater than 5.0 log units, while MAb 1D3 alone and sparfloxacin alone exerted 0.5 and 3.0 log units of killing, respectively. Additionally, the reduction in the weight of the lungs of treated mice was closely correlated to the intrapulmonary killing of bacteria. These in vivo effects of the combination of MAb 1D3 and a suboptimal dose of sparfloxacin may be partly caused by MAb-dependent, complement-mediated killing of bacteria in the presence of sub-MICs of sparfloxacin. Joiner and coworkers (7, 8, 28) reported on the mechanism of serum resistance for Salmonella minnesota, Eschenchia coli, and P. aeruginosa. These bacteria activated complement efficiently, and C5b-9 membrane attack complexes were formed on the bacterial surfaces. The C5b-9 complexes themselves were not bactericidal, because they did not insert into the hydrophobic outer membrane domains. However, the MAbs specific for the 0 side chain of E. coli O111:B4 LPS efficiently fixed complement and resulted in MAbdependent, complement-mediated cell lysis on serum-resistant homologous bacteria (15) . Furthermore, a recent report described the bacteriolysis of P. aeruginosa It-1 that was presensitized with a MAb specific for the 0 side chain by using higher concentrations of AbsNHS (22) . On the other hand, previous investigators showed that E. coli treated with a DNA gyrase inhibitor, nalidixic acid, became susceptible to detergent-mediated lysis (3) . After the addition of nalidixic acid, there were only slight changes in the synthesis of a few outer membrane proteins. Therefore, there was apparently a significant functional interaction between an LPSreactive MAb and sub-MICs of sparfloxacin that resulted in enhanced complement-mediated bacterial killing of P. aeruginosa It-1.
The data presented in this report suggest an important therapeutic interaction between LPS-reactive MAbs and antibiotics in a neutropenic mouse model of P. aeruginosa pneumonia and appear to provide a basis for the therapeutic strategy of LPS-reactive MAbs combined with antibiotics against life-threatening P. aeruginosa pneumonia in neutropenic patients.
